Add like
Add dislike
Add to saved papers

Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD Phase I trial.

BACKGROUND: Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the ER gene ( ESR1LBD m ). ESR1 mutational mediated resistance may be overcome by selective ER degraders (SERDs). During the first-in-human study of oral SERD AZD9496, early changes in circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) were explored as potential non-invasive tools, alongside paired tumor biopsies, to assess pharmacodynamics and early efficacy.

METHODS: CTC were enumerated/phenotyped for ER and Ki67 using CellSearch® in serial blood draws. ctDNA was assessed for the most common ESR1LBD m by droplet digital PCR (BioRad).

RESULTS: Before starting AZD9496, 11/43 (25%) patients had ≥5CTC/7.5mL whole blood (WB), none of whom underwent reduction to <5CTC/7.5mL WB on C1D15. 5/11 patients had baseline CTC-ER+, 2 of whom had CTC-ER+ reduction. CTC-Ki67 status did not change appreciably. Patients with ≥5CTC/7.5mL WB pre-treatment had worse progression-free survival (PFS) than patients with <5CTC (p=0.0003). Fourteen of 45 (31%) patients had ESR1LBD m + ctDNA at baseline, 5 of whom had ≥2 unique mutations. Baseline ESR1LBD m status was not prognostic. Patients with persistently elevated CTC and/or ESR1LBD m + ctDNA at C1D15 had worse PFS than patients who did not (p=0.0007).

CONCLUSIONS: Elevated CTC at baseline was a strong prognostic factor in this cohort. Early on-treatment changes were observed in CTC-ER+ and ESR1LBD m + ctDNA, but not in overall CTC number. Integrating multiple biomarkers in prospective trials may improve outcome prediction and ET resistance mechanisms' identification over a single biomarker.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app